202 related articles for article (PubMed ID: 6221746)
1. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
Harris AL; Dowsett M; Smith IE; Jeffcoate SL
Br J Cancer; 1983 May; 47(5):621-7. PubMed ID: 6221746
[TBL] [Abstract][Full Text] [Related]
2. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
Harris AL; Dowsett M; Smith IE; Jeffcoate S
Eur J Cancer Clin Oncol; 1984 Apr; 20(4):463-9. PubMed ID: 6233150
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
Dowsett M; Harris AL; Stuart-Harris R; Hill M; Cantwell BM; Smith IE; Jeffcoate SL
Br J Cancer; 1985 Oct; 52(4):525-9. PubMed ID: 2933050
[TBL] [Abstract][Full Text] [Related]
4. Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
Stuart-Harris R; Dowsett M; D'Souza A; Donaldson A; Harris AL; Jeffcoate SL; Smith IE
Clin Endocrinol (Oxf); 1985 Feb; 22(2):219-26. PubMed ID: 2985301
[TBL] [Abstract][Full Text] [Related]
5. Aminoglutethimide dose and hormone suppression in advanced breast cancer.
Harris AL; Dowsett M; Jeffcoate SL; Smith IE
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):493-8. PubMed ID: 6222901
[TBL] [Abstract][Full Text] [Related]
6. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
[TBL] [Abstract][Full Text] [Related]
7. Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer.
Alexieva-Figusch J; de Jong FH; Lamberts WJ; van Gilse HA; Klign JG
Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1349-56. PubMed ID: 2960533
[TBL] [Abstract][Full Text] [Related]
8. Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion.
Dowsett M; Mehta A; Cantwell BM; Harris AL
Eur J Cancer; 1991; 27(7):846-9. PubMed ID: 1657077
[TBL] [Abstract][Full Text] [Related]
9. Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861).
Bruning PF; Bonfrèr JM; Wildiers J; Jassem J; Beex LV; Schornagel J; Nooijen WJ
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1013-9. PubMed ID: 2149501
[TBL] [Abstract][Full Text] [Related]
10. Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer.
Bruning PF; Bonfrer JM; Hart AA; van der Linden E; de Jong-Bakker M; Moolenaar AJ; Nooijen WJ
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):369-76. PubMed ID: 2702989
[TBL] [Abstract][Full Text] [Related]
11. Influence of ACTH on aminoglutethimide induced reduction of plasma steroids in postmenopausal breast cancer.
Bruning PF; Bonfrer JM; De Jong-Bakker M; Nooyen W
J Steroid Biochem; 1984 Sep; 21(3):293-8. PubMed ID: 6092781
[TBL] [Abstract][Full Text] [Related]
12. High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer.
Harris AL; Cantwell BM; Dowsett M
Br J Cancer; 1988 Oct; 58(4):493-6. PubMed ID: 2974717
[TBL] [Abstract][Full Text] [Related]
13. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.
Harris AL; Dowsett M; Jeffcoate SL; McKinna JA; Morgan M; Smith IE
J Clin Endocrinol Metab; 1982 Oct; 55(4):718-22. PubMed ID: 6213633
[TBL] [Abstract][Full Text] [Related]
14. Adrenal suppression with aminoglutethimide. III. Comparison of plasma delta 4- and delta 5-steroids in postmenopausal women treated for breast carcinoma.
Samojlik E; Santen RJ
J Clin Endocrinol Metab; 1978 Oct; 47(4):717-24. PubMed ID: 162517
[TBL] [Abstract][Full Text] [Related]
15. Low-dose aminoglutethimide in treatment of advanced breast cancer.
Stuart-Harris R; Dowsett M; Bozek T; McKinna JA; Gazet JC; Jeffcoate SL; Kurkure A; Carr L; Smith IE
Lancet; 1984 Sep; 2(8403):604-7. PubMed ID: 6147642
[TBL] [Abstract][Full Text] [Related]
16. Adrenal effects of low-dose aminoglutethimide when used alone in postmenopausal women with advanced breast cancer.
Carella MJ; Dimitrov NV; Gossain VV; Srivastava L; Rovner DR
Metabolism; 1994 Jun; 43(6):723-7. PubMed ID: 8201961
[TBL] [Abstract][Full Text] [Related]
17. Observations on the pharmacokinetics of low dose aminoglutethimide in patients with advanced breast cancer.
Stuart-Harris R; Bradbrook I; Morrison P; Smith IE; Rogers HJ
Br J Cancer; 1985 Apr; 51(4):485-92. PubMed ID: 3978028
[TBL] [Abstract][Full Text] [Related]
18. Effects of aminoglutethimide on adrenal steroid secretion.
Vermeulen A; Paridaens R; Heuson JC
Clin Endocrinol (Oxf); 1983 Dec; 19(6):673-82. PubMed ID: 6652931
[TBL] [Abstract][Full Text] [Related]
19. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.
Dowsett M; MacNeill F; Mehta A; Newton C; Haynes B; Jones A; Jarman M; Lonning P; Powles TJ; Coombes RC
Br J Cancer; 1991 Nov; 64(5):887-94. PubMed ID: 1931611
[TBL] [Abstract][Full Text] [Related]
20. Aminoglutethimide in the treatment of advanced breast cancer.
Stuart-Harris RC; Smith IE
Cancer Treat Rev; 1984 Sep; 11(3):189-204. PubMed ID: 6241038
[No Abstract] [Full Text] [Related]
[Next] [New Search]
